37 results on '"Minola E"'
Search Results
2. Morphometric analysis of primary graft non-function in liver transplantation
3. A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone
4. Massive haemoptysis after living donor liver transplantation
5. Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C
6. Semiquantitative assessment of IgM antibody to hepatitis B core antigen and prediction of the severity of chronic hepatitis B
7. Clinical course of pregnant women with chronic hepatitis C virus infection and risk of mother-to-child hepatitis C virus transmission
8. Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.
9. Hierarchy of Baby-Linked Immunogenetic Risk Factors in the Vertical Transmission of Hepatitis C Virus.
10. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype.
11. Outbreak of Non-A, Non-B Hepatitis in Centre Haemodialysis Patients: A Retrospective Analysis.
12. Vitamin D Treatment: A Hidden Risk Factor for Aluminum Bone Toxicity?
13. Liver transplantation for hepatocellular carcinoma: prognostic factors associated long-term survival.
14. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C?
15. Apparent epidemic of HCV infection in a haemodialysis unit.
16. Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis.
17. T-12 Tenofovir suppressed viral suppression in most field practice, treatment-naïve patients with CHB followed for 3 years in a multicenter European study.
18. T-11 5-year entecavir in NUC-naïve, field-practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC.
19. P.15.11 A PROSPECTIVE CONTROLLED TRIAL ON THE EFFICACY AND TOLERABILITY OF ANTIVIRAL THERAPY IN ILLICIT DRUG USERS WITH CHRONIC HEPATITIS C RECEIVING METHADONE MAINTENANCE TREATMENT.
20. P.15.2 ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT.
21. OC.07.1 2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE.
22. T-9 2-year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice.
23. T-8 Entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B from field practice: high efficacy and favorable safety profile over 3 years of treatment.
24. OC.09.2: MAINTAINED LONG-TERM SUPPRESSION OF HBV REPLICATION IN NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH ETV MONOTHERAPY IN FIELD PRACTICE: THE ITALIAN MULTICENTER EXPERIENCE.
25. P.1.48: EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 737 PATIENTS WITH CHRONIC HEPATITIS B.
26. P.1.158: PEG-INTERFERON ALPHA-2A WITH WEIGHT-BASED RIBAVIRIN DOSES IN PATIENTS WITH CHRONIC HEPATITIS C AND PERSISTENTLY NORMAL TRANSAMINASES: A PILOT STUDY IN A SINGLE CENTRE.
27. F-34 Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice: The Italian multicenter experience.
28. F-36 Effectiveness and safety of tenofovir disoproxil fumarate in field practice: A multicenter European cohort study of 737 patients with chronic hepatitis B.
29. P.233 RETREATMENT WITH PEG-IFN ALPHA-2A PLUS RIBAVIRIN FOR 48 WEEKS IN CHRONIC HEPATITIS C GENOTYPE 2 AND 3 RELAPSERS TO A PREVIOUS ANTIVIRAL TREATMENT.
30. OC.03.2 ENTECAVIR FOR NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376 PATIENTS.
31. F.N.16 EFFECTIVENESS OF ENTECAVIR FOR NUC-NAIVE, HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY IN 311 PATIENTS.
32. EFFECTIVENESS OF ENTECAVIR FOR THE TREATMENT OF NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS: A LARGE MULTICENTER COHORT STUDY IN CLINICAL PRACTICE.
33. HCV genotype 2 and 3 respond differently to anti HCV treatment.
34. Older age is associated with an impaired response to combination pegylated interferon and ribavirin treatment for chronic hepatitis C.
35. Is hepatocellular carcinoma in cirrhosis an actual indication for liver transplantation?
36. INTERFERON THERAPY IN LIVER CIRRHOSIS ASSOCIATED WITH CHRONIC HEPATITIS C.
37. LYMPHOBLASTOID IFN-ALPHA VERSUS RECOMBINANT IFN-ALPHA.2a IN THE TREATMENT OF CHRONIC HCV HEPATITIS.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.